bluyahu -- you have to deduct the equity interest charge of 36.8% - which means the unnamed company really just paid 149,404,800 of the 219,652,578 additional (unregistered) shares.
Like you, I am in doubt that the metal that was exchanged for this additional shares are even worth that much!!!
And like you, I don't believe that this company should be valued a billion dollars by the market.
Anyway, I doubt if we will know if $NEWL will ever get a profit because the last time they reported any financial forms was last 2011 and that was a 200 million loss.
I reported NEWL to FINRA. Their recent press release was very misleading. A transaction with such materiality needs to have transparency not just in terms of who they are dealing with, but also on how it will affect the stock price, or at least they should have been honest on how much the shares they really sold or exchanged to the "investor".
thanks for clarifying. I'm lost at this format too.
But yeah, I hope that seeking alpha will make an article about it like what they did with that Chinese company who turned out to be a fraud.
This company is diluting like crazy, and this released is so laughable!
lol-- are you sure that you are replying to me? I didn't even mentioned anything about the tanker. Just deciphering the news that they RELEASED on some website.
lol -- did you read what I wrote? These are all facts taken from their press releases.
Anyone here with a brain who is willing to discuss this?
How do I contact seekingalpha?
Someone needs to investigate in this company and the deal with the un-named company!!
Let's go back to the last press in July 30, 2012. The company had a total of 482,252,385. The latest press release says that the company is expected to have 701,904,963 shares. Deduct that it means that they might be issuing about 219,652,578 shares total to this UNNAMED metal company exchanged for their metal product "valued" at 236.4 million FOR A 36.8% Equity Interest. Deducting this interest means we now have a total of 149,404,800.
Divide that to the number of shares. That should give us .68
So, why is the PPS 4x this number?
This isn't justifiable. It's not even CASH they are giving.
Something to think about.
NEWL financing was just a rumor. UNTIL they have not filed an SEC form about it, nothing is final!!! NEWL is heading down to $1 sooner than $5.
I checked and the last 6k was filed on December 20th regarding the listing requirement.
For many quarters now they show unusual expense of more than 2x the revenue due to lack of risk management in their firm.
I've been watching this company, and I would like to invest--but I may want more concrete evidence of a turn around besides this being the next "NEWL".
They have the CEO of Genzyme now on board. As you know, Sanofi-Genzyme focuses on rare disease that is why I think that Krystexxa would be something they will be interested on. There are other drugs out there for gout, but Krsytexxa is the only one that address those patients that were not responsive to other gout treatments.
"Cambridge, Mass. and Carlsbad, Calif., Dec. 14, 2012 – Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for its marketing authorization application (MAA) for KYNAMRO TM (mipomersen) for the treatment of patients with Homozygous Familial Hypercholesterolaemia (HoFH). Genzyme plans to request a re-examination of the CHMP Opinion."
-- somehow this makes me think that this failure might be a good thing for Savient. This makes krystexxa very appealing...
anyone seen the SEC filing? can someone please explain to me the form D? How come it says "decline to disclose the offering"? Total offering amount: 42,249,990 USD?
Any thoughts about this? Is this dilutive? How will this affect the price in the short term?
I am almost convinced to buy this stock, but I don't want surprises at the end. So, I would like to do my own diligence and research more about the potential of this clinical drug. I was kind of surprise that the website did not list the other name for z106. For example, Savient's krystexxa list pegloticase as the compound name, what about z106??
I don't want to invest in a compound/drug that has been around for decades passed from one biopharma to another. Even if it will be approved, it won't be safe, and most likely there is a problem with the drug. I'd hate to support something that will cause harm to our society.
Anyone please help me?
It's common sense really, start taking profit or else the market will take that opportunity from you and give it to someone else smart enough to understand the game.
There is no medal for being stup1d.
It's all fluff news, nothing concrete has been presented yet.
not only that-- this isn't the best in class drug out there. Big pharma isn't going to partner up with zalicus for this drug until many quarters after FDA marketing approval. Too early to be a die hard long. They need to start showing 80% gross margin before even thinking that they will get bought out.
Next news will just be a pump, so they could stay away from delisting, and start diluting their shares for the PHASE II clinical process. That thing isn't free, and without any financial support from other big pharma or government, the support has to come from shareholders.
where is your common sense? 90% of drugs pass phase I -
what's the big deal? this is not like a game changing event! fluff news!!